EUVIMEDEUVIMED entdecken
Open Access

Rab29-dependent asymmetrical activation of leucine-rich repeat kinase 2

Hanwen Zhu iD, Francesca Tonelli iD, Martin Turk iD, Alan Prescott iD, Dario R Alessi iD, Ji Sun iD

Science · 22.12.2023 · 382 (6677) · 1404-1411

DOI: 10.1126/science.adi9926 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science, erschienen am 22.12.2023. Verfasst von Hanwen Zhu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Structural Biology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA. Hauptthemen laut MEDLINE: Leucine-Rich Repeat Serine-Threonine Protein Kinase-2, Parkinson Disease, rab GTP-Binding Proteins. Die Arbeit wurde bisher 94-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Medical Research Council, NINDS NIH HHS, NHLBI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Gain-of-function mutations in LRRK2 , which encodes the leucine-rich repeat kinase 2 (LRRK2), are the most common genetic cause of late-onset Parkinson’s disease. LRRK2 is recruited to membrane organelles and activated by Rab29, a Rab guanosine triphosphatase encoded in the PARK16 locus. We present cryo–electron microscopy structures of Rab29–LRRK2 complexes in three oligomeric states, providing key snapshots during LRRK2 recruitment and activation. Rab29 induces an unexpected tetrameric assembly of LRRK2, formed by two kinase-active central protomers and two kinase-inactive peripheral protomers. The central protomers resemble the active-like state trapped by the type I kinase inhibitor DNL201, a compound that underwent a phase 1 clinical trial. Our work reveals the structural mechanism of LRRK2 spatial regulation and provides insights into LRRK2 inhibitor design for Parkinson’s disease treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leucine-Rich Repeat Serine-Threonine Protein Kinase-2Parkinson Diseaserab GTP-Binding ProteinsHumansAntiparkinson AgentsCatalytic DomainCryoelectron MicroscopyDrug DesignGain of Function MutationProtein SubunitsProtein MultimerizationProtein Kinase Inhibitors

Substanzen

Antiparkinson AgentsLeucine-Rich Repeat Serine-Threonine Protein Kinase-2Protein Subunitsrab GTP-Binding ProteinsRab29 protein, humanProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Structural Biology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.
  • MRC Protein Phosphorylation and Ubiquitylation Unit, School of Life Sciences, University of Dundee, Dundee DD1 5EH, UK.
  • Aligning Science Across Parkinson's (ASAP) Collaborative Research Network, Chevy Chase, MD, USA.
  • Cryo-EM and Tomography Center, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.

ORCID-Profile: Hanwen Zhu, Francesca Tonelli, Martin Turk, Alan Prescott, Dario R Alessi, Ji Sun

Förderung

  • Medical Research Council
  • NINDS NIH HHS
  • NHLBI NIH HHS

Zitieren

APA

Zhu, H., Tonelli, F., Turk, M., Prescott, A., Alessi, D. R., & Sun, J. (2023). Rab29-dependent asymmetrical activation of leucine-rich repeat kinase 2. Science, 382(6677), 1404-1411. https://doi.org/10.1126/science.adi9926

Vancouver

Zhu H, Tonelli F, Turk M, Prescott A, Alessi DR, Sun J. Rab29-dependent asymmetrical activation of leucine-rich repeat kinase 2. Science. 2023;382(6677):1404-1411. doi:10.1126/science.adi9926

BibTeX
@article{Zhu2023,
  author = {Zhu, Hanwen and Tonelli, Francesca and Turk, Martin and Prescott, Alan and Alessi, Dario R and Sun, Ji},
  title = {Rab29-dependent asymmetrical activation of leucine-rich repeat kinase 2},
  journal = {Science},
  year = {2023},
  volume = {382},
  number = {6677},
  pages = {1404--1411},
  doi = {10.1126/science.adi9926}
}
Kostenlos starten →